Paclitaxtide

紫杉肽

Report date: 2024/08/08 17:10:03
NME

Base Information

Drug NamePaclitaxtide
Drug Alias NamePaclitide
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionTubulin depolymerization inhibitors
TargetsTubulin
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesFannin Bioscience
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesSichuan Yuansheng Biological Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A